List of Publications by Year
in descending order

87 papers	6,580 citations	117453 34 h-index	62479 80 g-index
89 all docs	89 docs citations	89 times ranked	7138 citing authors

#	Article	IF	Citations
1	Dopamine Receptors: From Structure to Function. Physiological Reviews, 1998, 78, 189-225.	13.1	3,059
2	Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors. Journal of Biological Chemistry, 2003, 278, 20196-20202.	1.6	200
3	Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization. Molecular Pharmacology, 2008, 74, 59-69.	1.0	195
4	Anterior Pituitary Hypoplasia and Dwarfism in Mice Lacking the Dopamine Transporter. Neuron, 1997, 19, 127-138.	3.8	192
5	Induction of the unfolded protein response by Î±-synuclein in experimental models of Parkinsonâ€™s disease. Journal of Neurochemistry, 2011, 116, 588-605.	2.1	178
6	Review: Parkinson's disease: from synaptic loss to connectome dysfunction. Neuropathology and Applied Neurobiology, 2016, 42, 77-94.	1.8	163
7	Dopamine Uptake is Differentially Regulated in Rat Striatum and Nucleus Accumbens. Journal of Neurochemistry, 1985, 45, 51-56.	2.1	132
8	Î±-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. Journal of Cell Science, 2015, 128, 2231-2243.	1.2	99
9	From Î±-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease. Brain Research, 2012, 1476, 183-202.	1.1	89
10	D2 dopamine receptors associated with inhibition of dopamine release from rat neostriatum are independent of cyclic AMP. Neuroscience Letters, 1986, 71, 192-196.	1.0	79
11	Loss of Synaptic D1 Dopamine/N-Methyl-d-aspartate Glutamate Receptor Complexes in l-DOPA-Induced Dyskinesia in the Rat. Molecular Pharmacology, 2006, 69, 805-812.	1.0	75
12	Alphaâ€synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D₂/D₃ receptor activation. Journal of Neurochemistry, 2008, 106, 560-577.	2.1	74
13	The NMDA/D1 Receptor Complex as a New Target in Drug Development. Current Topics in Medicinal Chemistry, 2006, 6, 801-808.	1.0	72
14	The Contribution of<i>Î±</i>-Synuclein Spreading to Parkinsonâ€™s Disease Synaptopathy. Neural Plasticity, 2017, 2017, 1-15.	1.0	70
15	Nerve Growth Factor Regulates Dopamine D2 Receptor Expression in Prolactinoma Cell Lines via p75NGFR-Mediated Activation of Nuclear Factor-ÎºB. Molecular Endocrinology, 2002, 16, 353-366.	3.7	66
16	L-Î±-glycerylphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. European Journal of Pharmacology, 1992, 211, 351-358.	1.7	65
17	Redistribution of DAT/Î±-Synuclein Complexes Visualized by â€œIn Situâ€•Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease. PLoS ONE, 2011, 6, e27959.	1.1	62
18	Mitochondrial Dysfunction andÎ±-Synuclein Synaptic Pathology in Parkinsonâ€™s Disease: Whoâ€™s on First?. Parkinson's Disease, 2015, 2015, 1-10.	0.6	62

#	Article	IF	Citations
19	Epidermal Growth Factor Induces the Functional Expression of Dopamine Receptors in the GH3 Cell Line*. Endocrinology, 1991, 128, 13-20.	1.4	61
20	Nicotine-Induced Structural Plasticity in Mesencephalic Dopaminergic Neurons Is Mediated by Dopamine D3 Receptors and Akt-mTORC1 Signaling. Molecular Pharmacology, 2013, 83, 1176-1189.	1.0	61
21	GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Experimental Cell Research, 2014, 323, 100-111.	1.2	61
22	Repeated reserpine administration up-regulates the transduction mechanisms of D1 receptors without changing the density of [3H]SCH 23390 binding. Brain Research, 1989, 483, 117-122.	1.1	58
23	Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. Current Opinion in Pharmacology, 2010, 10, 87-92.	1.7	58
24	Nuclear Factor-ÎºB Dysregulation and Î±-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 68.	1.7	56
25	Synapsin III deficiency hampers Î±-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinsonâ€™s disease. Acta Neuropathologica, 2018, 136, 621-639.	3.9	53
26	Characterization of Dopamine Receptors Associated with Aldosterone Secretion in Rat Adrenal Glomerulosa*. Endocrinology, 1986, 119, 2227-2232.	1.4	48
27	Dopamine D3 receptorâ€preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signalâ€regulated kinase phosphorylation. European Journal of Neuroscience, 2008, 28, 1231-1240.	1.2	48
28	Identification and Characterization of Postsynaptic D1- and D2-Dopamine Receptors in the Cardiovascular System. Journal of Cardiovascular Pharmacology, 1988, 11, 643-650.	0.8	45
29	Identification and Characterization of Two Nuclear Factor-ÎºB Sites in the Regulatory Region of the Dopamine D2 Receptor. Endocrinology, 2007, 148, 2563-2570.	1.4	43
30	Preâ€synaptic dopamine D₃ receptor mediates cocaineâ€induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways. Journal of Neurochemistry, 2012, 120, 765-778.	2.1	43
31	Repeated administration of (âˆ’) sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions. European Journal of Pharmacology, 1987, 138, 45-51.	1.7	39
32	Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Research, 2012, 1432, 95-113.	1.1	39
33	Synapsin III is a key component of Î±â€synuclein fibrils in Lewy bodies of PD brains. Brain Pathology, 2018, 28, 875-888.	2.1	37
34	The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. Journal of Receptor and Signal Transduction Research, 2010, 30, 347-354.	1.3	36
35	The D3 dopamine receptor: From structural interactions to function. European Neuropsychopharmacology, 2015, 25, 1462-1469.	0.3	35
36	The â€œIn Situâ€•Proximity Ligation Assay to Probe Proteinâ€“Protein Interactions in Intact Tissues. Methods in Molecular Biology, 2014, 1174, 397-405.	0.4	35

#	Article	IF	Citations
37	Nerve Growth Factor in Pituitary Development and Pituitary Tumors. Frontiers in Neuroendocrinology, 1998, 19, 128-150.	2.5	34
38	Nerve growth factor signaling in prostate health and disease. Growth Factors, 2010, 28, 191-201.	0.5	33
39	Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease. Neurobiology of Disease, 2013, 54, 339-348.	2.1	33
40	Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4594-4602.	1.8	31
41	Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. II. Dorsal hippocampus. Neuroscience Letters, 1988, 87, 253-258.	1.0	30
42	Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure. Neurochemistry International, 2015, 85-86, 14-23.	1.9	30
43	Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. Molecular Neurobiology, 2018, 55, 1054-1067.	1.9	30
44	Palbociclib inhibits proliferation of human adrenocortical tumor cells. Endocrine, 2018, 59, 213-217.	1.1	28
45	Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection. Biomolecules, 2020, 10, 1016.	1.8	28
46	Dopamine D3 and acetylcholine nicotinic receptor heteromerization in midbrain dopamine neurons: Relevance for neuroplasticity. European Neuropsychopharmacology, 2017, 27, 313-324.	0.3	27
47	The tyrosine phosphatase Shpâ€2 interacts with the dopamine D₁ receptor and triggers D₁â€mediated Erk signaling in striatal neurons. Journal of Neurochemistry, 2011, 117, 253-263.	2.1	25
48	Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer. Neurobiology of Disease, 2019, 129, 1-12.	2.1	25
49	Evidence for the presence of D1 and D2 dopamine receptors in the rat adrenal cortex. European Journal of Pharmacology, 1985, 109, 315-316.	1.7	23
50	Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145. European Journal of Endocrinology, 2002, 147, 407-415.	1.9	22
51	In vitro antitumor activity of progesterone in human adrenocortical carcinoma. Endocrine, 2019, 63, 592-601.	1.1	21
52	Role of receptor heterodimers in the development of l-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, S159-S164.	1.1	20
53	Dopamine Transporter/Î±-Synuclein Complexes Are Altered in the Post Mortem Caudate Putamen of Parkinsonâ€™s Disease: An In Situ Proximity Ligation Assay Study. International Journal of Molecular Sciences, 2018, 19, 1611.	1.8	20
54	Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate. Neurobiology of Disease, 2020, 138, 104789.	2.1	19

#	Article	IF	Citations
55	Nerve Growth Factor Restores p53 Function in Pituitary Tumor Cell Lines via trkA-Mediated Activation of Phosphatidylinositol 3-Kinase. Molecular Endocrinology, 2004, 18, 162-172.	3.7	18
56	Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. I. Frontal cortex. Neuroscience Letters, 1988, 87, 247-252.	1.0	17
57	The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease. Experimental Neurology, 2017, 291, 1-7.	2.0	17
58	Identification of D-2 dopaminergic receptors in bovine adrenal cortex. Life Sciences, 1985, 37, 2539-2548.	2.0	15
59	Dopaminergic Regulation of Aldosterone Secretion. American Journal of Hypertension, 1990, 3, 93S-95S.	1.0	15
60	Growth factors in pituitary tumors. Pituitary, 1999, 1, 153-158.	1.6	15
61	Low doses of l-sulpiride down-regulate striatal and cortical dopamine receptors and Î²-adrenoceptors. European Journal of Pharmacology, 1991, 199, 247-253.	1.7	14
62	Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: Role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine. Molecular and Cellular Neurosciences, 2006, 31, 284-292.	1.0	14
63	Shpâ€2 knockdown prevents <scp>l</scp>â€dopaâ€induced dyskinesia in a rat model of Parkinson's disease. Movement Disorders, 2016, 31, 512-520.	2.2	14
64	The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons. Biochemical Pharmacology, 2019, 163, 154-168.	2.0	14
65	Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinsonâ€™s disease patients carrying the LRRK2 G2019S mutation. Neurobiology of Aging, 2021, 99, 65-78.	1.5	14
66	Striatal adenylate cyclase-inhibiting dopamine D2 receptors are not affected by the aging process. Neuroscience Letters, 1987, 75, 38-42.	1.0	13
67	Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. European Journal of Endocrinology, 2002, 147, 371-379.	1.9	12
68	Bifunctional compounds targeting both D2 and non-Î±7 nACh receptors: Design, synthesis and pharmacological characterization. European Journal of Medicinal Chemistry, 2015, 101, 367-383.	2.6	12
69	Repeated administration of lisuride down-regulates dopamine D-2 receptor function in mesostriatal and in mesolimbocortical rat brain regions. European Journal of Pharmacology, 1990, 176, 85-90.	1.7	11
70	Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 164-175.	1.3	11
71	Evidence for the presence of both D-1 and D-2 dopamine receptors in human esophagus. Life Sciences, 1990, 47, 447-455.	2.0	10
72	Opposing roles for D-1 and D-2 dopamine receptors in the regulation of lower esophageal sphincter motility in the rat. Life Sciences, 1994, 54, 1035-1045.	2.0	10

#	Article	IF	Citations
73	Epidermal Growth Factor Promotes Uncoupling from Adenylyl Cyclase of the Rat D_{2S} Receptor Expressed in GH4C1 Cells. Journal of Neurochemistry, 1994, 62, 907-915.	2.1	10
74	Differential effect of acute reserpine administration on D-1 and D-2 dopaminergic receptor density and function in rat striatum. Neurochemistry International, 1989, 14, 61-64.	1.9	9
75	Increased serum concentration of nerve growth factor in patients with microprolactinoma. Neuropeptides, 2004, 38, 21-24.	0.9	7
76	Dopaminergic Receptor Mechanisms Modulating the Renin-Angiotensin System and Aldosterone Secretion. Journal of Cardiovascular Pharmacology, 1989, 14, S29-S39.	0.8	6
77	Differential gene expression of dopamine D-2 receptor subtypes in rat chromaffin cells and sympathetic neurons in culture. NeuroReport, 2000, 11, 2467-2471.	0.6	6
78	Molecular and pharmacological detection of dopaminergic receptors in the human male urinary tract. Neurourology and Urodynamics, 2009, 28, 343-348.	0.8	6
79	Growth factors in the pathogenesis of prolactin-secreting tumors. Journal of Endocrinological Investigation, 1998, 21, 402-411.	1.8	5
80	Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway. Molecular Neurobiology, 2022, 59, 2129-2149.	1.9	5
81	Nerve growth factor, D2 receptor isoforms, and pituitary tumors. Endocrine, 2012, 42, 466-467.	1.1	4
82	Induced pluripotent stem cells for defining Parkinsonian patient subtypes: a further step toward precision medicine. Neural Regeneration Research, 2022, 17, 767.	1.6	4
83	Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor. Stem Cell Research, 2021, 51, 102216.	0.3	2
84	Effects of chronic treatment with L-alpha-glycerylphosphorylcholine on hippocampal cholinergic transmission in the rat. Drug Development Research, 1992, 27, 277-286.	1.4	1
85	Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression. Stem Cell Research, 2020, 49, 102104.	0.3	1
86	Recent Advances in Dopamine D3 Receptor Heterodimers: Focus on Dopamine D3 and D1 Receptorâ€“Receptor Interaction and Striatal Function. Current Topics in Behavioral Neurosciences, 2022, , 1.	0.8	1
87	Oligomerization of Dopamine D1 and Glutamate NMDA Receptors: A New Mechanism Regulating Striatal Function. , 2005, , 141-149.		0